Eyal Gottlieb, VP of Research at MD Anderson Cancer Center, shared a post on LinkedIn:
“At UT MD Anderson, we never stop exploring, collaborating, and sharing the joy of science across borders. Yesterday, we had the pleasure of hosting colleagues from Princess Margaret Cancer Centre for our annual Joint Research Symposium in Houston. A delegation of 12 investigators and leaders traveled from Toronto for a full day of scientific exchange, reinforcing the strength and momentum of this strategic partnership.
The symposium brought together leading experts in cancer genomics, therapy resistance, tumor host interactions, and novel therapeutics, spanning both discovery and translational science. Through plenary sessions and focused breakout discussions, we explored emerging mechanisms of cancer initiation and progression while identifying new opportunities for collaboration across our institutions. I had the privilege of chairing the breakout session on Tumor Host Interactions: Metabolic and Signaling Pathways, with outstanding talks from Aaron Schimmer, Hind Rafei, and Yuki Nishida.
What continues to set this partnership apart is not only the scientific excellence on both sides, but also the deliberate structure that helps turn ideas into action. The joint seed funding program is designed to catalyze cross institutional teams, providing paired investigators with the resources to pursue high impact early-stage projects with clear paths toward extramural funding and clinical translation.
These are not simply one day engagements. They are the foundation for sustained and meaningful collaboration. The energy and alignment throughout the symposium reflected a shared commitment to advancing bold, team-based science.
We look forward to building on this momentum with the upcoming launch of the next joint funding cycle, continuing to invest in innovative collaborations that accelerate discovery and ultimately improve outcomes for patients.”
Other articles featuring Eyal Gottlieb.